Erwinase® (crisantaspase) is an L-asparaginase enzyme derived from the bacterium Erwinia Chrysanthemi that is indicated for the treatment of Acute Lymphoblastic Leukaemia (ALL) a type of cancer that particularly affects children.
Developed at Porton in the 1960’s, PBL remains the sole global manufacturer of Erwinase® which was first registered as a product name in the UK in 1985. Since then it has been supplied to treat patients in numerous countries around the world.
Patient Information Leaflet (PIL)
For additional information on Erwinase® including possible side effects please see the patient information leaflet (PIL).
This link will take you to electronic Medicines Compendium (eMC) website which is a non PBL website.
Become part of the team
If you are a motivated person who is interested in working in a high-tech environment as part of a dynamic team, then there could be a role for you.